X-Chem delivers excellence, innovation and efficiency at each stage of drug discovery. Since 2012, our medicinal chemists have been named as co-inventors on 24 projects, have filed over 100 patents and published more than 65 scientific papers. Our impressive track record includes 17 compounds reaching IND-enabling toxicology studies and seven compounds progressing to Phase I clinical trials or beyond.
Hit → Lead → Candidate: Click through our proven track record of reliability, efficiency and success.
Kinases
Target:
PINK1 activator, EC50=ca. 500 nM
Therapy Area:
Neurodegeneration
Protein-Protein Interaction
Target:
Bromodomain
Therapy Area:
Cancer/Autoimmune/Inflammation
Protein-Protein Interaction
Target:
Bromodomain
Therapy Area:
Cancer/Autoimmune/Inflammation
Protein-Protein Interaction
Target:
Bromodomain
Therapy Area:
Cancer/Autoimmune/Inflammation
Protein-Protein Interaction
Target:
Bromodomain
Therapy Area:
Inflammation
Receptors
Target:
PAR2
Therapy Area:
Cancer
Protein-Protein Interaction
Target:
KEAP1
Therapy Area:
CNS
Receptors
Target:
CXCR7
Therapy Area:
Cardioprotection
Enzymes
Target:
EED & PRC2 Modulators
Therapy Area:
Sickle Celled Anemia
Protein-Protein Interaction
Target:
NLRP3
Therapy Area:
Inflammation
Kinases
Target:
PINK1
Therapy Area:
CNS
Transcription Factors
Target:
FOXO1
Therapy Area:
Diabetes
Receptors
Target:
H4
Therapy Area:
Inflammation/Pain/Autoimmune
ION Channels
Target:
Sodium Channel
Therapy Area:
CNS